GSK turns to Camp4 for neuro and kidney medicines

GSK will enlist regulatory RNA biotech Camp4 Therapeutics to help find and create new neurodegenerative and kidney disease medicines.

The deal is worth $17.5 million upfront, and as much as $440 million in development and …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844